Aarti Drugs Limited Approves Leadership Transition: Rashesh C. Gogri Elevated to Chairman, Adhish P. Patil Appointed Managing Director

Aarti Drugs Limited Approves Leadership Transition: Rashesh C. Gogri Elevated to Chairman, Adhish P. Patil Appointed Managing Director​

Aarti Drugs Limited, a leading pharmaceutical company, announced significant changes to its senior management structure following a Board meeting held on July 31, 2026. The company confirmed the elevation of Shri Rashesh C. Gogri to the position of Chairman and the appointment of Shri Adhish P. Patil as Managing Director, effective October 1, 2026.

The leadership transition marks a strategic step by Aarti Drugs Limited (ADL) aimed at strengthening governance and ensuring long-term strategic growth as the company continues to scale its operations across manufacturing and R&D capabilities.

Key Appointments and Succession Planning​

Shri Prakash M. Patil will be stepping down from his executive roles as Chairman, Managing Director, and Chief Executive Officer. He has been associated with ADL since its inception and held the position of Chairman since 2014. His transition is set to occur effective September 30, 2026, though he will continue providing guidance and strategic support to the company for a smooth handover.

The key changes in leadership are detailed below:


Shri Rashesh C. Gogri has been a Managing Director at the company since September 2014 and served as a Whole-time Director since October 2012. He holds a degree in Production Engineering from Mumbai University and possesses over 27 years of experience in chemical and pharmaceutical industries, covering production, marketing, and project implementation.

Shri Adhish P. Patil has been with Aarti Drugs Limited since April 2014 as Chief Financial Officer. He holds a Bachelor of Engineering (IT) degree from Mumbai University and an MBA in Finance and Marketing from the University of Florida's Warrington College of Business Administration. His appointment as Managing Director is subject to shareholder approval at the upcoming Annual General Meeting.

Perspectives on Leadership Shift​

Shri Prakash M. Patil commented on the changes, stating that it has been a privilege to help build Aarti Drugs from its early days into its current form. He expressed complete confidence in Shri Rashesh C. Gogri and Shri Adhish P. Patil, looking forward to contributing through guidance and strategic support during the transition period while supporting the company's next phase of growth.

Shri Rashesh C. Gogri shared his vision for the role, noting that he looks forward to building upon the foundation of scientific rigor and quality at Aarti Drugs. He aims to deepen capabilities across the API and formulations businesses and pursue future opportunities with the discipline that has defined the company.

Shri Adhish P. Patil stated that he is honored by the Board's confidence. Having spent over a decade within the organization in finance and operations, he looks forward to working with the team to sharpen execution, deepen competitiveness, and create lasting value for all stakeholders.

The leadership transition is designed to facilitate a natural evolution of ADL’s governance framework. This realignment preserves deep institutional knowledge and technical expertise while positioning the company for greater speed and clarity across manufacturing, R&D, and commercial functions.

About Aarti Drugs Limited​

Aarti Drugs Limited was established in 1984 and operates as part of the $6 Billion Aarti Group of Industries. The company is engaged in the manufacture of Active Pharmaceutical Ingredients (APIs), Pharma Intermediates, Specialty Chemicals, and Formulations via its subsidiary, Pinnacle Life Science Private Limited.

ADL maintains a robust R&D Division located at Tarapur and operates 14 manufacturing facilities across Maharashtra (10), Gujarat (3), and Himachal Pradesh (1). Products under APIs include Ciprofloxacin Hydrochloride, Metronidazole, and Ketoconazole. Specialty Chemicals products include Benzene Sulphonyl Chloride and Methyl Nicotinate.

AARTIDRUGS Stock Price Movement​

Aarti Drugs Limited shares rallied on Friday, closing at ₹422.75 after gaining 2.47%. The stock saw a trading volume of 187,361 shares as it finished the session in positive territory.